Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

OMNICELL, INC. Director's Dealing 2017

Nov 17, 2017

31980_dirs_2017-11-17_4b4303a4-887a-4502-8681-ff31ebf68529.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OMNICELL, Inc (OMCL)
CIK: 0000926326
Period of Report: 2017-11-17

Reporting Person: JOHNSTON DAN S (EVP-Chief Legal & Admin Off)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-11-17 Common Stock S 6413 $47.7637 Disposed 37208 Direct
2017-11-17 Common Stock S 8200 $47.8436 Disposed 29008 Direct
2017-11-17 Common Stock M 8200 Acquired 37208 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-11-17 Nq Stock Options (right to buy) $16.70 M 4100 Acquired 2022-07-02 Common Stock (4100) Direct
2017-11-17 Nq Stock Options (right to buy) $17.29 M 4100 Acquired 2023-02-05 Common Stock (4100) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 43621 Direct

Footnotes

F1: The price reported in Column 4 is the average price of $47.7637. The shares sold between $47.40 to $48.00. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: F2 The price reported in Column 4 is the average price of $47.8436. The shares sold between $47.40 to $48.00. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan